Sveriges mest populära poddar
BioCentury This Week
VetenskapLife Science

Ep. 111 - Seeking Green Shoots Amid Biotech’s Gloom

18 min•14 april 2022

Positive fund flows and modestly better performance by biotech indexes offer hints that the beginnings of a recovery could be possible in the near term, even as the financing drought grinds on. On a BioCentury This Week Special Report, BioCentury’s editors discuss the conditions, including clinical catalysts and M&A, that could spark a recovery for the biopharma sector. This week’s podcast is sponsored by Bio€quity Europe.

Reach us by sending a text

Fler avsnitt av BioCentury This Week

Visa alla avsnitt av BioCentury This Week
Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision
•29 min
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
•34 min
Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline
•25 min
Ep. 354 - East-West Summit Takeaways
•26 min
Ep. 353 - Prasad Departure and Future of Fibrosis Therapies
•37 min
Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight
•35 min
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
•35 min
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA
•26 min
Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch
•34 min
Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules
•31 min

BioCentury This Week med BioCentury finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.